Clinical Trials Browser

Phase 1/2 × Hematologic Neoplasms × Breast × Clear all

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT00526045 2020-12-17

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Phase 1/2 Completed

117 enrolled

BreastOther hematologic neoplasm

Breast Neoplasms, Hematologic Neoplasms

NCT02431260 2019-06-14

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Phase 1/2 Terminated

69 enrolled 34 charts

BreastGastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Primary Myelofibrosis

Clinical Trials

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies